The US FDA recently approved the Therascreen PIK3CA RGQ polymerase chain reaction assay as a companion diagnostic for detecting PIK3CA breast cancer mutations in both tissue and liquid biopsies, suggesting future applications for liquid breast cancer biopsy in clinical decision-making. This evidence concerns the gene PIK3CA and breast cancer.